A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The IES study (A5991012) investigated 4742 patients treated for 2 to 3 years with tamoxifen,
who either continued the same treatment or switched to Aromasin® for a total treatment period
of 5 years. Only 65 Romanian patients were enrolled in the IES study. It would therefore
appear to be essential to evaluate and confirm the tolerability of Aromasin® and the ways in
which it is used on a broader sample of patients and under the standard conditions of use as
stipulated in the MA. This Non-Interventional study was designed to address these issues.